Trial Profile
A single-center, open-label investigator-sponsored phase I study for propranolol/etodolac in combination with nanoparticle albumin-bound-paclitaxel and gemcitabine in metastatic pancreatic cancer patients
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 Jan 2015
Price :
$35
*
At a glance
- Drugs Propranolol/etodolac (Primary) ; Gemcitabine; Paclitaxel
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 22 Jan 2015 New trial record
- 16 Jan 2015 Results were presented at the 2015 Gastrointestinal Cancers Symposium, according to a Vicus Therapeutics media release.
- 16 Jan 2015 Results published in a Vicus Therapeutics media release.